Letter to the EditorRecurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas
Section snippets
Conflict of interest statement
None declared.
References (22)
- et al.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Eur J Cancer
(2016) - et al.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Lancet
(2014) - et al.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Lancet Oncol
(2015) - et al.
Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy
Ann Oncol
(2017) - et al.
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Ann Oncol
(2015) - et al.
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Eur J Cancer
(2016) Annular pancreas in the adult
Am J Surg
(1970)Chronic pancreatitis, pseudotumors and other tumor-like lesions
Mod Pathol
(2007)- et al.
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
N Engl J Med
(2015) - et al.
Nivolumab in previously untreated melanoma without BRAF mutation
N Engl J Med
(2015)
Pembrolizumab versus ipilimumab in advanced melanoma
N Engl J Med
(2015)
Cited by (0)
© 2017 Elsevier Ltd. All rights reserved.